Gold Price Reaches for $1,400

Source: The Street, Alix Steel (12/1/10)

"Investors fled to gold as protection against a eurozone debt crisis."

Gold prices were closing in on $1,400 an ounce Wednesday as investors fled into the safe haven asset as protection against a eurozone debt crisis.

Gold for February delivery was adding $6.70 to $1,392.80 an ounce at the Comex division of the New York Mercantile Exchange. The gold price Wednesday has traded as high as $1,398.30 and as low as $1,383.

The U.S. dollar index was losing 0.87% to $80.58 while the euro stemmed losses and was rising 1.22% to $1.31 vs. the dollar. The spot gold price was up $2.20, according to Kitco's gold index.

Gold prices were setting their sights on $1,400 for the second time this year and reached new highs in euros as European sovereign debt fears heated up. Gold soared 1.3% Tuesday as the euro hit a 10-week low against the dollar as investors worried Belgium, Portugal, Spain and Italy might be the next countries to need a bailout.

"Default speculation will continue to dominate sentiment in the coming days," says James Moore, analyst at thebulliondesk.com. "Short-term, bullion. . .remains vulnerable to bouts of long liquidation. . .[but] Europe's debt problems. . .are supportive to further price gains." Investors will turn their sights on Europe again Thursday as the European Central Bank meets to discuss interest rates.

Gold was getting additional support Wednesday from a jump in risk appetite, which boosted the euro and hurt the dollar. The weaker dollar was helping gold's advance as the dollar-backed became less expensive to buy.

World-wide purchasing managers indices, which measure the health of the sector, came in higher than expected. China's November PMI rose to 55.2, France's rose to 57.9, Germany's fell slightly to 58.1, but any number over 50 indicates growth. Even eurozone PMI came in at 55.3 and the U.K's rose to 58.

Novavax Shares Shoot 65% Higher on Phase 3 COVID-19 Vaccine Trial's 89.3% Effectiveness
Source: Streetwise Reports (01/29/2021)

Novavax Inc. shares established a new 52-week high after the firm's COVID-19 vaccine demonstrated an 89.3% efficacy rate in a Phase 3 trial in the U.K. and also showed efficacy against the South African variant in a Phase 2b trial.

Abiomed Shares Gain 8% After Firm Announces Record Q3 Revenue of $232 Million
Source: Streetwise Reports (01/28/2021)

Shares of cardiac medical device maker Abiomed Inc. traded higher after the company reported record revenue for Q3/21 despite the impact from COVID-19.

Sorrento Shares Rise 35% After Firm Posts Positive Data from Phase 1b ICU COVID-19 Trial
Source: Streetwise Reports (01/27/2021)

Shares of Sorrento Therapeutics traded higher after the company released positive preliminary results from it of Phase 1b COVI-MSC™ Study for treatment of hospitalized ICU COVID-19 patients.

Junior Mining Sector 'the Best Value in the Space'
Source: Streetwise Reports (01/27/2021)

The StreetSmart Live! Broadcast on Jan. 26, 2021, focused on metals and why now is a good time for investors to be looking at them and the mining space. John Newell, independent analyst and portfolio manager, and John Feneck, mining sector expert and president of Feneck Consulting, addressed the status of the current metals market. CEOs of the three metals-focused companies comprising the Metallic Group of Companies—Group Ten Metals, Metallic Minerals and Granite Creek Copper—discussed their projects.

Vir Shares Climb 48% on Initial Phase 1 Chronic Hepatitis B Trial Data
Source: Streetwise Reports (01/26/2021)

Vir Biotechnology shares traded higher after the company reported data from its Phase 1 Chronic Hepatitis B Study that showed VIR-3434 significantly and rapidly reduced hepatitis B surface antigen.

Aurinia Pharma Shares Open at 52-Week High as FDA Approves Adult Lupus Nephritis Drug
Source: Streetwise Reports (01/25/2021)

Shares of Aurinia Pharmaceuticals traded 30% higher after the company reported that the U.S. Food and Drug Administration approved its LUPKYNIS™ (voclosporin) for use in treating adults with active lupus nephritis.

AzurRx Doses First Two People in Expanded Phase 2b Trial of Cystic Fibrosis Patients
Source: Streetwise Reports (01/22/2021)

AzurRx BioPharma shares traded 45% higher after the firm advised it had dosed the first two patients in its Phase 2b OPTION 2 Extension Study of MS1819 for treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis.

NGL Energy Shares Rise 21% as It Seeks to Raise $2.05 Billion from Senior Secured Note Offering
Source: Streetwise Reports (01/21/2021)

Shares of NGL Energy Partners LP traded higher after the firm made a series of announcements over the past three days regarding an update on financial operations, a settlement with a customer in bankruptcy, a quarterly Class D unit distribution and a $2.05 billion senior secured debt offering.

Explorer Discovers New Gold Mineralization at Abitibi Gold Belt Property
Source: Streetwise Reports (01/21/2021)

iMetal Resources is setting out to see if the multi-million ounce gold resource next door continues onto its Gowganda West property in Ontario.

Gritstone Oncology Licenses LNP Platform from Genevant Sciences to Develop COVID-19 Vaccine
Source: Streetwise Reports (01/20/2021)

Shares of Gritstone Oncology reached a new 52-week high price after the company advised it entered into a non-exclusive licensing agreement with Genevant Sciences to develop and commercialize self-amplifying RNA vaccines for use against SARS-CoV-2.